Epidermal growth factor receptor gene and c‐erbB‐2 gene amplification in ovarian cyst fluid
暂无分享,去创建一个
[1] B. Casslén,et al. Fluid Characteristics of Benign Ovarian Cysts: Correlation With Recurrence After Puncture , 1995, Obstetrics and gynecology.
[2] B. Gerber,et al. Histologie und Zytologie laparoskopisch operierter „simpler Ovarialzysten“ , 1995 .
[3] L. Zentilin,et al. Gene amplification for c-erbB-2, c-myc, epidermal growth factor receptor, int-2, and N-myc measured by quantitative PCR with a multiple competitor template. , 1995, Clinical chemistry.
[4] W. Creasman,et al. Ovarian cancer screening. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] J. Olson,et al. Reliability of Differential PCR for the Detection of EGFR and MDM2 Gene Amplification in DNA Extracted from FFPE Glioma Tissue , 1995, Journal of neuropathology and experimental neurology.
[6] R. Scully,et al. p53 expression in ovarian borderline tumors and stage I carcinomas. , 1994, American journal of clinical pathology.
[7] R. Scully,et al. Early de novo ovarian carcinoma. A study of fourteen cases , 1994, Cancer.
[8] A. Harłozińska,et al. Relationship between p53 and c-erbB-2 overexpression in tissue sections and cyst fluid cells of patients with ovarian cancer. , 1994, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.
[9] J. Papp,et al. Oncogene patterns in breast and ovarian carcinomas. , 1993, European Journal of Surgical Oncology.
[10] S. Leodolter,et al. HER-2 and INT-2 amplification estimated by quantitative PCR in paraffin-embedded ovarian cancer tissue samples. , 1993, European journal of cancer.
[11] R. Kryscio,et al. Transition from benign to malignant epithelium in mucinous and serous ovarian cystadenocarcinoma. , 1992, Gynecologic oncology.
[12] B. Ljung,et al. The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast. , 1992, Oncogene.
[13] A. Neubauer,et al. Analysis of gene amplification in archival tissue by differential polymerase chain reaction. , 1992, Oncogene.
[14] R. Ozols,et al. Ovarian cancer biology. , 1991, Seminars in oncology.
[15] R. Bast,et al. Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. II. Relationship between receptor expression and response to epidermal growth factor , 1991, American journal of obstetrics and gynecology.
[16] R. Bast,et al. Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. , 1991, American journal of obstetrics and gynecology.
[17] Anita B. Roberts,et al. Peptide Growth Factors and Their Receptors I , 1990, Springer Study Edition.
[18] G. Carpenter,et al. The Epidermal Growth Factor Family , 1991 .
[19] J. Foekens,et al. Prognostic value of pS2 protein and receptors for epidermal growth factor (EGF-R), Insulin-like growth factor-1 (IGF-1-R) and somatostatin (SS-R) in patients with breast and ovarian cancer , 1990, The Journal of Steroid Biochemistry and Molecular Biology.
[20] E. Liu,et al. Detection of amplified oncogenes by differential polymerase chain reaction. , 1989, Oncogene.
[21] W Godolphin,et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.
[22] T. Bauknecht,et al. Occurrence of epidermal growth factor receptors in human adnexal tumors and their prognostic value in advanced ovarian carcinomas. , 1988, Gynecologic oncology.
[23] N. Nomura,et al. Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor , 1986, Nature.
[24] P. Seeburg,et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells , 1984, Nature.
[25] D. Goeddel,et al. Structure of the human immune interferon gene , 1982, Nature.